C4 Therapeutics Inc (NAS:CCCC)
$ 4.99 -0.01 (-0.2%) Market Cap: 343.34 Mil Enterprise Value: 155.56 Mil PE Ratio: 0 PB Ratio: 1.33 GF Score: 53/100

C4 Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript

Jun 01, 2021 / 02:30PM GMT
Release Date Price: $37.46 (+1.38%)
Kelly Shi
Jefferies, LLC - Analyst

Good morning, everyone. My name is Kelly Shi, one of the biotech analysts at Jefferies. Thank you for attending our virtual healthcare conference. We are very pleased to have C4 Therapeutics team, Mr. Andrew Hirsch, President and the CEO; Mr. Adam Crystal, CMO; and Mr. Stewart Fisher, CSO, join our fireside chat session.

C4 Therapeutics is a pioneer in targeted protein degrader technology, which is a broader concept than [PROTAC]. And this is a technology -- we can also call it a space now, as of today, has attracted a lot of attention from pharma and the biotech industry.

Andrew, maybe you can share with us your insights. What makes TPD a promising and appealing technology among all of the therapeutic modalities such as the small molecule inhibitors, antibodies, or even RA interferons?

Andrew Hirsch
C4 Therapeutics, Inc. - President and CEO

Sure. Thanks, Kelly, [for introducing] us. So, you are right. It is a really exciting field and we are really excited to be a leader in this field. I think what is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot